Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Address
2nd Floor, 38 Sidney Street
CAMBRIDGE, MA 02139-4169
United States
CAMBRIDGE, MA 02139-4169
United States
Website
www.agios.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -137.52% | -80.07% |
| Operating margin | -136.02% | -91.59% |
| EBITD margin | - | -86.90% |
| Return on average assets | -29.16% | -12.13% |
| Return on average equity | - | - |
| Employees | 85 |
